Health · Pharma & Biotech · 1 hr ago
Syndax ends Niktimvo development for lung disease after Phase 2 failure
Syndax is ending development of Niktimvo as a treatment for idiopathic pulmonary fibrosis, or IPF.
IPF is a rare lung disease.
The treatment failed a Phase 2 trial, a mid-stage study of a medicine.
The result means Syndax will not continue developing Niktimvo for this disease.
The trial failure ends Niktimvo’s prospects for IPF in Syndax’s development programme.
The available information does not say what the company plans to do next.
Syndax is ending development of Niktimvo for idiopathic pulmonary fibrosis after the treatment failed a Phase 2 trial.
The article describes idiopathic pulmonary fibrosis as a rare lung disease.
- Who
- Syndax.
- What
- The company is ending development of Niktimvo for idiopathic pulmonary fibrosis after the treatment failed a mid-stage trial.
- When
- The article was published on 2026-10-13.
- Where
- Not stated.
- Why
- The treatment failed a Phase 2 trial.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Niktimvo
- Company
- Syndax
- Disease
- Idiopathic pulmonary fibrosis (IPF)
- Trial stage
- Phase 2
Sources
Related news
Early research links GLP-1 drugs to signs of slower biological aging
Experts raise safety concerns about Neurocrine’s Prader-Willi drug
US FDA supports planned trial of StemSmart therapy for Crohn’s disease
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
